NICE Approves Wegovy for 1.2M Britons to Cut Heart Attack Stroke Risk
Key Takeaways
- NHS to offer Wegovy to 1.2 million overweight patients at risk of cardiovascular events.
- Eligible individuals include those with heart or circulatory conditions.
- Wegovy is semaglutide; already used for obesity and diabetes.
Wegovy Goes Beyond Weight Loss
NICE approved Wegovy for about 1.2 million people in England at high risk of heart attack or stroke.
“Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement Today's Paper Advertisement Companies Healthcare & Fitness Weight loss Print article Andrew Tillett and Michael Smith Updated Mar 31, 2026 – 2”
The drug will be offered to people who have had a heart attack, stroke, or serious circulation problem in their legs and have a BMI of 27 or above.
Drug trials showed the jabs could reduce cardiovascular risk even before significant weight loss occurred.
NHS Rollout to Start Soon
NHS England will offer the drug alongside existing heart medicines and a healthy diet.
Health Minister Sharon Hodgson called the drugs a game changer and life saver.
The move represents a rapid expansion from Wegovy's previous NHS use.
Trial Found 20% Risk Reduction
The approval followed a major clinical trial involving 17,604 people.
“Wegovy weight loss jab to be offered to 1”
Semaglutide reduced the risk of death from heart problems by 20% regardless of weight loss.
Experts described the decision as a major turning point in the battle against obesity.
More on Technology and Science
Baidu's Apollo Go Robotaxis Halt in Wuhan; 100+ Vehicles Stranded in Traffic
15 sources compared
NASA Launches Artemis II: Four Astronauts Begin Historic Lunar Orbit Mission
13 sources compared
NASA Launches Artemis II, First Crewed Lunar Flyby Since Apollo
19 sources compared
New York City Reverses TikTok Ban, Allows Use With Security Protocols
12 sources compared